Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ. Zhuang J, et al. Among authors: jones rj. Blood. 2019 Apr 4;133(14):1572-1584. doi: 10.1182/blood-2018-06-859686. Epub 2019 Feb 8. Blood. 2019. PMID: 30737236 Free PMC article.
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, Punt S, Williams L, Haymaker C, Chesson CB, Fa'ak F, Dominguez AL, Jones R, Kuiatse I, Caivano AR, Khounlo S, Warier ND, Marathi U, Market RV, Biediger RJ, Craft JW Jr, Hwu P, Davies MA, Woodside DG, Vanderslice P, Diab A, Overwijk WW, Hailemichael Y. Hickman A, et al. Among authors: jones r. J Clin Invest. 2022 Jul 1;132(13):e154152. doi: 10.1172/JCI154152. J Clin Invest. 2022. PMID: 35552271 Free PMC article.
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, Wang H, Lee HC, Patel KK, Wan J, Choudhary RK, Kuiatse I, Pahl A, Orlowski RZ. Singh RK, et al. Among authors: jones rj. Res Sq [Preprint]. 2024 Jan 11:rs.3.rs-3843028. doi: 10.21203/rs.3.rs-3843028/v1. Res Sq. 2024. PMID: 38260385 Free PMC article. Preprint.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: jones rj. Blood. 2025 Jan 7:blood.2024025154. doi: 10.1182/blood.2024025154. Online ahead of print. Blood. 2025. PMID: 39775763
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ. Holtan SG, et al. Among authors: jones rj. J Clin Oncol. 2025 Jan 3:JCO2400921. doi: 10.1200/JCO.24.00921. Online ahead of print. J Clin Oncol. 2025. PMID: 39752608
Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma.
Tabbara N, Zahurak ML, Sterling C, Trutzer IM, Jedrych J, Swinnen LJ, Fuchs EJ, Bolaños-Meade J, Wagner-Johnston ND, Jones RJ, Ambinder RF, Varadhan R, Paul S. Tabbara N, et al. Among authors: jones rj. Blood Adv. 2024 Dec 18:bloodadvances.2024015048. doi: 10.1182/bloodadvances.2024015048. Online ahead of print. Blood Adv. 2024. PMID: 39693511
761 results